{"transactions":[{"id":707925,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock Purchase Warrant","published_at":"2026-07-16T20:01:04.000Z","date":"2026-07-14","kind":"purchase","planned":false,"acquired":true,"shares":34364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the \"Initial Exercise Date\").  \"Authorized Share Increase Date\" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The term of exercise is equal to five and one-half years after the Initial Exercise Date."}],"balance_after":34364,"derivative":{"exercise_price":1.33,"underlying":"Common Stock","underlying_shares":34364},"source":{"system":"sec-edgar","filing":"0001193125-26-306072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526306072/ownership.xml","form_type":"4"}},{"id":707924,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-16T20:01:04.000Z","date":"2026-07-14","kind":"purchase","planned":false,"acquired":true,"shares":34364,"price":1.455,"value":49999.62,"ownership":{"direct":true},"balance_after":59067,"source":{"system":"sec-edgar","filing":"0001193125-26-306072","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526306072/ownership.xml","form_type":"4"}},{"id":730153,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T20:50:35.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":59000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2027 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":59000,"derivative":{"exercise_price":2.96,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":59000},"source":{"system":"sec-edgar","filing":"0001610717-26-000278","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071726000278/form4.xml","form_type":"4"}},{"id":730230,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-06-22T13:00:05.000Z","date":"2026-06-18","kind":"purchase","planned":false,"acquired":true,"shares":24703,"price":1.21,"value":29890.63,"ownership":{"direct":true},"balance_after":24703,"source":{"system":"sec-edgar","filing":"0001664708-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000166470826000002/ownership.xml","form_type":"4"}},{"id":819163,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Options","published_at":"2026-04-02T20:16:32.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":600000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"150,000 vest on March 31, 2027 and 12,500 vest monthly for 36 months thereafter"}],"balance_after":968766,"derivative":{"exercise_price":1.62,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":600000},"source":{"system":"sec-edgar","filing":"0001193125-26-140164","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526140164/ownership.xml","form_type":"4"}},{"id":896138,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO"}}],"security":"Stock Options","published_at":"2026-02-18T21:01:02.000Z","date":"2026-02-17","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":368766,"derivative":{"exercise_price":1.56,"exercise_date":"2026-05-17","expiration_date":"2036-02-17","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001193125-26-056994","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000119312526056994/ownership.xml","form_type":"4"}},{"id":1099111,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2025-06-30T13:38:05.000Z","date":"2025-06-26","kind":"grant","planned":false,"acquired":true,"shares":40565,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":168766,"derivative":{"exercise_price":3.16,"exercise_date":"2026-06-26","expiration_date":"2035-06-26","underlying":"Common Stock","underlying_shares":40565},"source":{"system":"sec-edgar","filing":"0001641172-25-017070","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000164117225017070/ownership.xml","form_type":"4"}},{"id":1111130,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:18:19.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2026 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":2.82,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-25-000213","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071725000213/form4.xml","form_type":"4"}},{"id":1465597,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2024-07-01T20:09:12.000Z","date":"2024-06-27","kind":"grant","planned":false,"acquired":true,"shares":29700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":128201,"derivative":{"exercise_price":2.33,"exercise_date":"2025-06-27","expiration_date":"2034-06-27","underlying":"Common Stock","underlying_shares":29700},"source":{"system":"sec-edgar","filing":"0001628280-24-030641","document":"wk-form4_1719864546.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828024030641/wk-form4_1719864546.xml","form_type":"4"}},{"id":1510697,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-17T21:34:38.000Z","date":"2024-05-15","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":38000,"derivative":{"exercise_price":1.98,"expiration_date":"2034-05-14","underlying":"Common Stock","underlying_shares":38000},"source":{"system":"sec-edgar","filing":"0001610717-24-000246","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071724000246/form4.xml","form_type":"4"}},{"id":1849145,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2023-06-20T21:03:26.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":27700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":98501,"derivative":{"exercise_price":1.59,"exercise_date":"2024-06-15","expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":27700},"source":{"system":"sec-edgar","filing":"0001628280-23-022732","document":"wk-form4_1687294992.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828023022732/wk-form4_1687294992.xml","form_type":"4"}},{"id":1851578,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T21:52:58.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2024 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.57,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001610717-23-000182","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000161071723000182/form4.xml","form_type":"4"}},{"id":2227052,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T20:07:24.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2023 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":1.72,"expiration_date":"2032-06-14","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001567619-22-013074","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761922013074/doc1.xml","form_type":"4"}},{"id":2339541,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2022-03-10T23:42:22.000Z","date":"2022-03-09","kind":"grant","acquired":true,"shares":26800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70801,"derivative":{"exercise_price":2.5,"exercise_date":"2023-03-09","expiration_date":"2032-03-09","underlying":"Common Stock","underlying_shares":26800},"source":{"system":"sec-edgar","filing":"0001628280-22-005794","document":"wf-form4_164695571887372.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828022005794/wf-form4_164695571887372.xml","form_type":"4"}},{"id":2663095,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-17T22:48:16.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of the grant date or (ii) the date of the 2022 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director until such vesting date."}],"balance_after":20000,"derivative":{"exercise_price":7.13,"expiration_date":"2031-06-15","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001567619-21-012372","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761921012372/doc1.xml","form_type":"4"}},{"id":2669860,"issuer":{"id":6917,"kind":"organization","name":"Cardiff Oncology, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options","published_at":"2021-06-14T20:12:51.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":44001,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"14,667 vest on 6/10/2022, 6/10/2023, and 6/20/2024"}],"balance_after":44001,"derivative":{"exercise_price":7.98,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":44001},"source":{"system":"sec-edgar","filing":"0001628280-21-012175","document":"wf-form4_162370155455648.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1213037/000162828021012175/wf-form4_162370155455648.xml","form_type":"4"}},{"id":2937434,"issuer":{"id":5124,"kind":"organization","name":"CytomX Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-18T21:41:35.000Z","date":"2020-12-16","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option vest on each monthly anniversary measured from December 16, 2020 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date."}],"balance_after":40000,"derivative":{"exercise_price":7.45,"expiration_date":"2030-12-15","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001567619-20-021372","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1501989/000156761920021372/doc1.xml","form_type":"4"}},{"id":3352286,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-12-05T00:50:59.000Z","date":"2019-12-04","kind":"sale","acquired":false,"shares":4755,"price":17.05,"value":81072.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2)."}],"balance_after":17441,"source":{"system":"sec-edgar","filing":"0001209191-19-059183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119059183/doc4.xml","form_type":"4"}},{"id":3352285,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-12-05T00:50:59.000Z","date":"2019-12-02","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares that vested under a performance-based restricted stock unit award (the \"RSU\") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on December 2, 2019. The vested shares represents the second of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer."}],"balance_after":22196,"source":{"system":"sec-edgar","filing":"0001209191-19-059183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119059183/doc4.xml","form_type":"4"}},{"id":3459691,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-07-17T21:46:04.000Z","date":"2019-07-15","kind":"exercise","acquired":false,"shares":37431,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth (1/4th) of the 385,000 shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date."}],"balance_after":299444,"derivative":{"exercise_price":14.06,"expiration_date":"2027-08-15","underlying":"Common Stock","underlying_shares":37431},"source":{"system":"sec-edgar","filing":"0001209191-19-042480","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119042480/doc4.xml","form_type":"4"}},{"id":3459690,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-07-17T21:46:04.000Z","date":"2019-07-15","kind":"sale","acquired":false,"shares":37431,"price":25,"value":935775.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 - $25.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4."}],"balance_after":13863,"source":{"system":"sec-edgar","filing":"0001209191-19-042480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119042480/doc4.xml","form_type":"4"}},{"id":3459689,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-07-17T21:46:04.000Z","date":"2019-07-15","kind":"exercise","acquired":true,"shares":37431,"price":14.06,"value":526279.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."}],"balance_after":51294,"source":{"system":"sec-edgar","filing":"0001209191-19-042480","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119042480/doc4.xml","form_type":"4"}},{"id":3507276,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-05-30T22:17:50.000Z","date":"2019-05-29","kind":"sale","acquired":false,"shares":2496,"price":21.39,"value":53389.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":13863,"source":{"system":"sec-edgar","filing":"0001209191-19-033517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119033517/doc4.xml","form_type":"4"}},{"id":3507275,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-05-30T22:17:50.000Z","date":"2019-05-28","kind":"grant","acquired":true,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares that vested under a performance-based restricted stock unit award (the \"RSU\") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on May 28, 2019. The vested shares represent one-third of the total number of shares subject to the award, and the remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer."}],"balance_after":16359,"source":{"system":"sec-edgar","filing":"0001209191-19-033517","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119033517/doc4.xml","form_type":"4"}},{"id":3592443,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-15T20:42:50.000Z","date":"2019-03-13","kind":"exercise","acquired":false,"shares":16041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the 385,000 shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date."}],"balance_after":336875,"derivative":{"exercise_price":14.06,"expiration_date":"2027-08-15","underlying":"Common Stock","underlying_shares":16041},"source":{"system":"sec-edgar","filing":"0001209191-19-019712","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119019712/doc4.xml","form_type":"4"}},{"id":3592442,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-03-15T20:42:50.000Z","date":"2019-03-13","kind":"sale","acquired":false,"shares":16041,"price":19.12,"value":306703.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."}],"balance_after":8026,"source":{"system":"sec-edgar","filing":"0001209191-19-019712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119019712/doc4.xml","form_type":"4"}},{"id":3592441,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-03-15T20:42:50.000Z","date":"2019-03-13","kind":"exercise","acquired":true,"shares":16041,"price":14.06,"value":225536.46,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."}],"balance_after":24067,"source":{"system":"sec-edgar","filing":"0001209191-19-019712","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119019712/doc4.xml","form_type":"4"}},{"id":3603827,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-03-08T22:32:52.000Z","date":"2019-03-06","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 6, 2019, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date."}],"balance_after":75000,"derivative":{"exercise_price":16.1,"expiration_date":"2029-03-06","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-19-018220","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119018220/doc4.xml","form_type":"4"}},{"id":3712683,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2019-01-02T22:54:28.000Z","date":"2018-12-28","kind":"sale","acquired":false,"shares":4500,"price":12.55,"value":56475.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a \"sell to cover\" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the restricted stock units reported in the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on December 31, 2018, and does not represent a discretionary trade by the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents the number of shares required to be sold by the Reporting Person to cover tax withholding described above."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.53 - $12.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4."}],"balance_after":8026,"source":{"system":"sec-edgar","filing":"0001209191-19-000403","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919119000403/doc4.xml","form_type":"4"}},{"id":3715832,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2018-12-31T21:17:01.000Z","date":"2018-12-27","kind":"grant","acquired":true,"shares":12526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the vesting in full of a performance-based restricted stock unit award based on the Issuer's satisfaction of certain performance criteria. In light of the performance-based vesting conditions of the award, such award was not reportable under Section 16 until vesting was determined, which occurred on December 27, 2018. Each restricted stock unit represented the contingent right to receive one share of common stock of the Issuer."}],"balance_after":12526,"source":{"system":"sec-edgar","filing":"0001209191-18-064403","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919118064403/doc4.xml","form_type":"4"}},{"id":3760654,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-11-16T21:22:04.000Z","date":"2018-11-15","kind":"exercise","acquired":false,"shares":16042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the 385,000 shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date."}],"balance_after":352916,"derivative":{"exercise_price":14.06,"expiration_date":"2027-08-15","underlying":"Common Stock","underlying_shares":16042},"source":{"system":"sec-edgar","filing":"0001209191-18-058944","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919118058944/doc4.xml","form_type":"4"}},{"id":3760653,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2018-11-16T21:22:04.000Z","date":"2018-11-15","kind":"sale","acquired":false,"shares":16042,"price":18.5,"value":296777.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-058944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919118058944/doc4.xml","form_type":"4"}},{"id":3760652,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2018-11-16T21:22:04.000Z","date":"2018-11-15","kind":"exercise","acquired":true,"shares":16042,"price":14.06,"value":225550.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise and corresponding sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."}],"balance_after":16042,"source":{"system":"sec-edgar","filing":"0001209191-18-058944","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919118058944/doc4.xml","form_type":"4"}},{"id":3786348,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2018-10-19T20:32:49.000Z","date":"2018-10-17","kind":"exercise","acquired":false,"shares":16042,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth (1/4th) of the shares subject to this option vested and became exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date."}],"balance_after":368958,"derivative":{"exercise_price":14.06,"expiration_date":"2027-08-15","underlying":"Common Stock","underlying_shares":16042},"source":{"system":"sec-edgar","filing":"0001209191-18-055685","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919118055685/doc4.xml","form_type":"4"}},{"id":3786347,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2018-10-19T20:32:49.000Z","date":"2018-10-17","kind":"sale","acquired":false,"shares":16042,"price":20.19,"value":323887.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 7, 2018."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.72 - $20.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-055685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919118055685/doc4.xml","form_type":"4"}},{"id":3786346,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Common Stock","published_at":"2018-10-19T20:32:49.000Z","date":"2018-10-17","kind":"exercise","acquired":true,"shares":16042,"price":14.06,"value":225550.52,"ownership":{"direct":true},"balance_after":16042,"source":{"system":"sec-edgar","filing":"0001209191-18-055685","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919118055685/doc4.xml","form_type":"4"}},{"id":4225337,"issuer":{"id":7579,"kind":"organization","name":"Tvardi Therapeutics, Inc."},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & Chief Strategy Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2017-08-24T21:52:12.000Z","date":"2017-08-15","kind":"grant","acquired":true,"shares":385000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-fourth (1/4th) of the shares shall vest and become exercisable on August 15, 2018; the balance of the shares shall vest and become exercisable in a series of 36 successive equal monthly installments measured from August 15, 2018, subject to the reporting person's continuous service with the issuer as of each such date."}],"balance_after":385000,"derivative":{"exercise_price":14.06,"expiration_date":"2027-08-15","underlying":"Common Stock","underlying_shares":385000},"source":{"system":"sec-edgar","filing":"0001209191-17-050188","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1346830/000120919117050188/doc4.xml","form_type":"4"}},{"id":4443109,"issuer":{"id":8401,"kind":"organization","name":"CURIS INC"},"owners":[{"id":30048,"kind":"person","name":"Mohindru Mani","position":1,"cik":"0001664708","reported_name":"Mohindru Mani","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Strategy Officer"}}],"security":"Employee stock option (right to buy)","published_at":"2017-02-16T21:36:38.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":424000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests as to 25% of the shares on January 1, 2018 and as to an additional 6.25% of the original shares each successive three month period through and until January 1, 2021."}],"balance_after":424000,"derivative":{"exercise_price":2.63,"expiration_date":"2027-02-13","underlying":"Common stock","underlying_shares":424000},"source":{"system":"sec-edgar","filing":"0001209191-17-011478","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1108205/000120919117011478/doc4.xml","form_type":"4"}}]}